Dow Jumps Over 100 Points; US Housing Starts Rise In April
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Wednesday. Following the market opening Wednesday, the...
Source: businessinsider.com
Page 7 - Intercept Pharmaceutical News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Intercept Pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Intercept Pharmaceutical Today - Breaking & Trending Today
Intercept Pharmaceuticals Investigated by Block & Leviton For Potential ...
Intercept Pharmaceuticals Investigated by Block & Leviton For Potential ...
Source: pr-inside.com
Intercept receives orphan drug designation for liver disease combo therapy
The FDA granted orphan drug status to Intercept’s therapy, which combines the approved Ocaliva with another drug called bezafibrate.
Source: pharmaceutical-technology.com
Jefferies Financial Group Comments on Intercept Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:ICPT)
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT – Get Rating) – Analysts at Jefferies Financial Group issued their Q2 2024 earnings estimates for shares of Intercept Pharmaceuticals in a research report issued on Thursday, April 27th. Jefferies Financial Group analyst M. Yee anticipates that the biopharmaceutical company will post earnings per share of ($0.06) for the quarter. The […]
Source: theenterpriseleader.com
Madrigal Drug Meets FDA's Twin Goals for NASH, Paving Way for FDA Filing
A Madrigal Pharmaceuticals drug for the fatty liver disease NASH has data from a pivotal clinical trial showing improvements in the organ. Based on those results, which sent Madrigal's stock price soaring more than 200%, the biotech is planning to seek what could become the first regulatory approval of a therapy for this metabolic disorder.
Source: medcitynews.com